The Phase III trial results of Hetero’s Movfor (Molnupiravir), presented at the Conference on Retroviruses and Opportunistic Infections (CROI) demonstrated that Molnupiravir along with Standard of Care (SOC) reduced the risk of hospitalisation by over 65% compared to SOC alone.
